PSMA PET scanning is being led internationally by the St Vincent’s group under Professor Louise Emmett and Professor Phillip Stricker.
Recently the PRIMARY study, a world first, was published in European Urology, the most coveted and highest impact urology journal in the world. It has also received an award as the best scientific presentation for 2021, an significant honour.
The consequences of this study is that less men with an elevated PSA will have unnecessary biopsies and less cancers will be missed as a result of the accurate targeting with PSMA PET scanning. It is even possible that in the future, biopsies for more advanced disease will be unnecessary. This is a world landmark study and is leading on to the second trial, the primary 2 trial .